sj-docx-1-smo-10.1177_20503121231181267 – Supplemental material for Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction

Autor: Syed, Saad, Khan, Reda, Khurram, Fahmida, Khan, Faiza Humayun, Safi, Danish, Safi, Salah Ud Din

Supplemental material, sj-docx-1-smo-10.1177_20503121231181267 for Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction by Saad Syed, Reda Khan, Fahmida Khurr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8fbdb540cd8fb5a402da8049188a082

Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction.

Autor: Syed, Saad, Khan, Reda, Khurram, Fahmida, Khan, Faiza Humayun, Safi, Danish, Safi, Salah Ud Din

Publikováno v: SAGE Open Medicine; 6/22/2023, p1-7, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review.

Autor: Khan MA; Internal Medicine, University of Kansas Medical Center, Kansas City, USA., Khan FH; Internal Medicine, Khyber Medical University, Peshawar, PAK., Khan HB; Physiology, Khyber Medical College, Peshawar, PAK., Saadeh C; Rheumatology, Allergy ARTS Clinic, Amarillo, USA., Davey N; Rheumatology, Allergy ARTS Clinic, Amarillo, USA.

Publikováno v: Cureus [Cureus] 2023 May 27; Vol. 15 (5), pp. e39553. Date of Electronic Publication: 2023 May 27 (Print Publication: 2023).